Glaucoma device controls IOP in high-risk PK

Article

The Ahmed glaucoma device (AGD) effectively controls intraocular pressure (IOP) with high-risk penetrating keratoplasty, reveal the findings from a study in the journal Cornea.

The Ahmed glaucoma device (AGD) effectively controls intraocular pressure (IOP) with high-risk penetrating keratoplasty, reveal the findings from a study in the journal Cornea.

Dr Almousa Radwan et al., The Corneoplastic Unit and Eye Bank, Queen Victoria Hospital, East Grinstead, West Sussex, UK, conducted a retrospective, non-comparative case series on 59 eyes that had high-risk PK. All patients underwent AGD insertion and the primary outcome measures were IOP control between 6 and 21 mmHg and corneal graft survival. The secondary outcome measures were risk factors linked with IOP control and corneal graft survival.

The team found that mean IOP reduced significantly after AGD insertion, with a median follow up of 78 months after insertion. IOP control was effective in 44 eyes with 96% of eyes maintaining IOP at 1 year, 87% at 2 years, 83% at 3 years and 83% at 5 years.

The percentage of clear corneal grafts after 1, 2, 3 and 5 years after AGD insertion were 87%, 77%, 65% and 47%, respectively. Post-valve surgery doubles the risk of failure to control IOP, but AGD effectively maintains IOP.

The abstract can be accessed here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.